Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FAP-targeted immunosuppressive CAR-DC
- Development stage
- Phase 1
- Lead developer
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intravenous
01
Overview
FAP-targeted immunosuppressive CAR-DC is an autologous cell therapy being developed by the Second Affiliated Hospital, School of Medicine, Zhejiang University for the treatment of end-stage idiopathic pulmonary fibrosis (IPF). The therapy utilizes chimeric antigen receptor (CAR) technology applied to dendritic cells (DCs) rather than T cells. These engineered immunosuppressive CAR-DCs (iCAR-DCs) are designed to specifically target fibroblast activation protein (FAP), which is highly expressed on pathological CTHRC1+ fibroblasts—the primary drivers of collagen production and irreversible scarring in IPF. By localizing to fibrotic lung areas, these cells aim to attenuate fibrosis and improve patient survival without eliciting detrimental immune responses or systemic toxicity.
- Other names
- CAR-DC-Second Affiliated Hospital, School of Medicine, Zhejiang University-idiopathic pulmonary fibrosisFAP-targeted iCAR-DC
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on FAP-targeted immunosuppressive CAR-DC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FAP-targeted immunosuppressive CAR-DC.